Exclusive speaker interview with SCHOTT Pharmaceutical Systems released for Pre-Filled Syringes East Coast 2019

SMi Group8 - 9 April 2019, Boston, USA.
The 6th Annual Pre-Filled Syringes East Coast conference is returning to Boston, USA. The two-day event will bring together specialists within the industry to provide an exclusive insight into the sphere of regulation, new digital technology trends, human studies and innovative design and delivery systems within the prefilled syringe industry.

In the run up to the conference, SMi Group caught up with Patrick Gallagher, Business Development Manager, SCHOTT Pharmaceutical Systems, to discuss his upcoming presentation, and his thoughts on the current challenges and opportunities in the pre-filled syringes field.

A snapshot of Patrick Gallagher's interview

Q: The Pre-Filled Syringes market has matured greatly over recent years, what key differences have you noticed in the last year regarding significant developments? A: "In recent years, we have seen quite a bit of interest from pharmaceutical companies to differentiate through delivery device, whether through lifecycle management of a biologic drug into a more complex device or by converting a legacy drug from vial to pre-filled syringe. PFS and cartridge-based primary containers can improve patient safety through less dose preparation and greater ease of use, as well as facilitate the transition of drug administration from a hospital to homecare setting, thus improving patient outcomes."

Q: What do you see as the greatest challenge for you to overcome personally in the pre-filled syringes field at the moment? A: "As an industry, we are still in the early stages of developing connected health solutions and while we are starting to generate significant data it will take some time to best realize how to use this data. Pharma and Medtech companies will need to continue to educate key healthcare stakeholders that device-generated data can improve patient outcomes and drive down healthcare costs."

The full speaker interview and more content including the latest brochure, past attendees list, and other exclusive speaker interviews can be found on the DOWNLOADS section on the website at http://www.pfsamericas.com/pr7

About SMi Group

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network.

Most Popular Now

Sanofi and GSK sign agreements with the Government…

Sanofi and GSK have signed agreements with the Government of Canada for the supply of up to 72 million doses of an adjuvanted COVID-19 vaccine, beginning in 2021. Thom...

BioNTech and Pfizer initiate rolling submission to…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the initiation of a rolling submission to the European Medicines Agency (EMA) for BNT162b2, the lea...

Johnson & Johnson initiates pivotal global Pha…

Johnson & Johnson (NYSE: JNJ) (the Company) announced the launch of its large-scale, pivotal, multi-country Phase 3 trial (ENSEMBLE) for its COVID-19 vaccine candidate, J...

Scientists trace severe COVID-19 to faulty genes a…

More than 10 percent of young and healthy people who develop severe COVID-19 have misguided antibodies that attack not the virus, but the immune system itself, new resear...

Vir Biotechnology and GSK announce global expansio…

Vir Biotechnology, Inc. (Nasdaq: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) announced the global expansion to Phase 3 of the COMET-ICE (COVID-19 Monoclonal antibody Eff...

Johnson & Johnson announces European Commissio…

Johnson & Johnson (NYSE: JNJ) (the Company) announced the European Commission (EC), acting on behalf of the European Union (EU) Member States, has approved an Advance Pur...

Johns Hopkins researchers publish COVID-19 'predic…

Using a combination of demographic and clinical data gathered from seven weeks of COVID-19 patient care early in the coronavirus pandemic, Johns Hopkins researchers today...

Web resources bring new insight into COVID-19

Researchers around the world are a step closer to a better understanding of the intricacies of COVID-19 thanks to two new web resources developed by investigators at Bayl...

COVID-19 vaccine AZD1222 clinical trial resumed in…

The Phase I/II clinical trial for the COVID-19 vaccine AZD1222 has resumed in Japan after discussion with the Japanese Pharmaceuticals and Medical Devices Agency (PMDA). ...

COVID-19 Long-Acting AntiBody (LAAB) combination A…

AstraZeneca's long-acting antibody (LAAB) combination, AZD7442, will advance into two Phase III clinical trials in more than 6,000 participants at sites in and outside th...

Adequate levels of vitamin D reduces complications…

Hospitalized COVID-19 patients who were vitamin D sufficient, with a blood level of 25-hydroxyvitamin D of at least 30 ng/mL (a measure of vitamin D status), had a signif...

Protective antibodies persist for months in surviv…

People who survive serious COVID-19 infections have long-lasting immune responses against the virus, according to a new study led by researchers at Massachusetts General ...